<?xml version="1.0" encoding="UTF-8"?>
<p id="Par52">From a public health perspective influenza continues to be the only human disease that requires annual vaccination. It is estimated that replacing just 10% of seasonal vaccines with a universal vaccine would avert 6300 influenza-related deaths and save 1.1 billion US dollars in direct healthcare costs per year in the United States alone [
 <xref ref-type="bibr" rid="CR44">44</xref>]. In 2017, the National Institute of Allergy and Infectious Diseases (NIAID) in the US laid out a detailed strategic plan for the development of a universal influenza vaccine, highlighting knowledge gaps and research areas in pursuit of this common goal [
 <xref ref-type="bibr" rid="CR43">43</xref>]. In their outline, they established four criteria for a universal influenza vaccine as: 
 <bold>75% effectiveness against symptomatic influenza infection, protection against both group I and group II influenza viruses, durable protection that last at least 1 year, and be suitable for all age groups.</bold> It is with these criteria in mind that we discuss various vaccine candidates being developed (Table 
 <xref rid="Tab1" ref-type="table">1</xref>).
</p>
